RTX Corporation is set to release its Q3 2026 earnings report on October 20, with Wall Street expecting earnings of $1.78 per share and revenue around $24.1 billion. The company has a strong record of beating earnings estimates for four consecutive quarters and has seen its shares rise 18.4% over the past year. RTX's valuation is attractive, trading below industry average forward earnings, supported by steady demand in aerospace and defense sectors. Investors will watch for the impact of supply-chain challenges and whether RTX raises its full-year guidance again.
RTX Corporation's Q3 2026 earnings preview provides context for Industrials-sector activity on Pluang. As of Oct 20, 2026 03:01 WIB, out of 135 priced US Industrials stocks, 46 rose and 88 fell. Notable movers include BYRN at USD 5.17 with a 1-day change of +6.82% and a Pluang order activity skewed 63% Sell / 37% Buy, contrasting with PLUG at USD 1.39, down 6.40% but with 82% Buy orders and a longer typical hold time of 42 days.
ICICI Bank reported a 20.1% year-over-year rise in standalone profit after tax to INR 148.43 billion for Q2 FY2027, surpassing earnings estimates with ADR earnings of $0.44 per share versus $0.41 expected. Revenue slightly exceeded forecasts at $3.52...
The Canadian Investment Regulatory Organization (CIRO) has temporarily halted trading of all shares of Bighorn Metals Corp. (symbol HRNY) as of 1:10 PM ET on October 19, 2026. The halt is pending further information from the company and aims to maint...
The HCA Healthcare Foundation awarded $25,000 to Waypoint (formerly Virginia Home for Boys and Girls) to expand its network of adults trained to support youth mental wellness across Virginia. This funding supports Waypoint's Therapeutic Resources tea...
Angle Advisors has appointed Chris Gessner as a Managing Director, bringing over 20 years of experience in corporate finance, including lending, private equity, and M&A advisory. Gessner's background spans various transaction types and industries suc...
The FDA has approved Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. This approval is based on the AZUR-1 trial showing 68% of patients achieved complete clinical response ...
